Literature DB >> 30066417

Idiopathic Portal Hypertension.

Virginia Hernández-Gea1,2,3, Anna Baiges1,2,3, Fanny Turon1,2,3, Juan Carlos Garcia-Pagán1,2,3,4.   

Abstract

Idiopathic portal hypertension (IPH) is a rare disorder characterized by clinical portal hypertension in the absence of a recognizable cause such as cirrhosis. Laboratory tests often reveal a preserved liver function with anemia, leukopenia, and thrombocytopenia due to splenomegaly. Imaging studies reveal signs of portal hypertension, whereas liver stiffness and portal pressure values are usually normal or slightly elevated. Liver biopsy is considered mandatory in order to rule out other causes of portal hypertension, mainly cirrhosis. Liver histology may only show subtle or mild changes, and the definite diagnosis of IPH often requires an expert pathologist and a high-quality specimen. The most frequent clinical presentation is variceal bleeding. Ascites is rarely observed initially, although it may occasionally appear during follow-up. Typical histological findings associated with IPH have been described in patients without portal hypertension, probably representing early stages of the disease. Although the pathophysiology of this entity remains largely unknown, it is frequently associated with underlying immunological disorders, bacterial infections, trace metal poisoning, medications, liver circulatory disturbances, and thrombotic events. The long-term prognosis of patients with IPH, where ascites and the underlying condition are important prognostic factors, is better than in patients with cirrhosis. Treatments that modify the natural history of the disease remain an unmet need, and management of IPH is frequently restricted to control of portal hypertension-related complications.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 30066417     DOI: 10.1002/hep.30132

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, and Skin Changes (POEMS) Syndrome and Idiopathic Portal Hypertension: A Rare Association.

Authors:  Fatima Belabbes; Youssefi Houda; Abderahmane Al Bouzidi; Youssef Bennani; Maryame Ahnach
Journal:  Cureus       Date:  2022-05-11

Review 2.  Morphometric changes and imaging findings of diffuse liver disease in relation to intrahepatic hemodynamics.

Authors:  Kumi Ozaki; Kazuto Kozaka; Yasuo Kosaka; Hirohiko Kimura; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2020-04-28       Impact factor: 2.374

3.  Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities.

Authors:  Asif Nashiry; Shauli Sarmin Sumi; Salequl Islam; Julian M W Quinn; Mohammad Ali Moni
Journal:  Brief Bioinform       Date:  2021-03-22       Impact factor: 11.622

Review 4.  Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease.

Authors:  Oana Nicoară-Farcău; Ioana Rusu; Horia Stefănescu; Marcel Tanțău; Radu Ion Badea; Bogdan Procopeț
Journal:  World J Gastroenterol       Date:  2020-06-14       Impact factor: 5.742

Review 5.  Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It.

Authors:  Angela Puente; Jose Ignacio Fortea; Carmen Del Pozo; Patricia Huelin; Maria Luisa Cagigal; Marina Serrano; Joaquin Cabezas; Maria Teresa Arias Loste; Paula Iruzubieta; Antonio Cuadrado; Susana Llerena; Carlos Lopez; Emilio Fábrega; Javier Crespo
Journal:  Cells       Date:  2019-11-24       Impact factor: 6.600

6.  Sigmoid Colon Varices due to Massive Thrombosis of a Noncirrhotic Extrahepatic Portosystemic Shunt.

Authors:  Manabu Hayashi; Tatsuro Sugaya; Masashi Fujita; Jun Nakamura; Hiromichi Imaizumi; Kazumichi Abe; Atsushi Takahashi; Tadayuki Takagi; Takuto Hikichi; Hiromasa Ohira
Journal:  Intern Med       Date:  2020-07-14       Impact factor: 1.271

7.  Living donor liver transplantation for idiopathic portal hypertension with focal nodular hyperplasia.

Authors:  Yoshiaki Tanji; Kenei Furukawa; Yosuke Igarashi; Mitsuru Yanagaki; Koichiro Haruki; Yoshihiro Shirai; Tomohiko Taniai; Takeshi Gocho; Norimitsu Okui; Toru Ikegami
Journal:  Surg Case Rep       Date:  2022-04-21

8.  Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension.

Authors:  Nikolaj Worm Ørntoft; Michel Blé; Anna Baiges; Jose Ferrusquia; Virginia Hernández-Gea; Fanny Turon; Marta Magaz; Søren Møller; Holger Jon Møller; Juan Carlos Garcia-Pagan; Henning Gronbaek
Journal:  Front Physiol       Date:  2021-06-11       Impact factor: 4.566

9.  An Autopsy Case of Multicentric Castleman Disease Presenting with Severe Jaundice.

Authors:  Yuichi Yamazaki; Yuka Yoshida; Megumi Shimizu; Takeshi Kobayashi; Hiroki Tojima; Ken Sato; Satoru Kakizaki; Hiroshi Handa; Hideaki Yokoo; Toshio Uraoka
Journal:  Intern Med       Date:  2021-06-05       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.